Rocket Pharmaceuticals Ltd.

GRAND CAYMAN, E9 · Founded 2015 · CIK 0001663128 · Biotech · Public

Gene therapy treatments for rare genetic diseases

rocketpharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$28M
2 Form D · Mar 2017
115 months since last filing
Contracts
—
No federal contracts on record
Patents
9
1 granted · 8 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$16,425,000
Private capital raisedForm D · SEC$12,024,787
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2467Vaxart, Inc.—$23M
2468PULMOTECT, INC—$22M
2469New Echota Biotechnology——
2470Rocket Pharmaceuticals Ltd.—$28M
2471BIOSTRATEGIES LC——
2472Fulgent Pharma LLC—$5.4M
2473Kestrel Therapeutics Inc.—$21M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Gaurav ShahExecutive Officer
  • Roderick WongDirector
  • Naveen YalamanchiDirector

Patents

USPTO · 1 granted of 9
  • Gene Therapy Vectors For Treatment Of Danon Diseasegranted
  • Gene Therapy Vectors For Treatment Of Danon Diseaseapplication
  • Gene Therapy Vectors For Treatment Of Danon Diseaseapplication
  • Gene Therapy Vectors For Infantile Malignant Osteopetrosisapplication
  • Gene Therapy For Cns Degenerationapplication
  • Gene Therapy Vectors For Treatment Of Danon Diseaseapplication
  • Production methods for viral vectorsapplication
  • Methods For Gene Modification Of Hematopoietic Cellsapplication
  • Gene Therapy Vectors For Treatment Of Danon Diseaseapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.